18F-PSMA PET/CT Versus 18F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective study shows PSMA PET/CT reclassifies metastatic stage in high-risk prostate cancer, suggesting improved treatment decisions.

Use of PSMA PET/CT resulted in significant metastatic stage migration for 40 patients.
Rate of extrapelvic lymph node metastases increased from 16% to 27%, emphasizing PSMA's diagnostic accuracy.
21 patients had treatment plans changed, indicating a shift towards more intensified systemic therapy.
Analysis was conducted based on the Wilcoxon signed-rank tests to validate the findings.

Madsen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark